Literature DB >> 18171316

Uses and safety profile of ciclosporin in ophthalmology.

Shahram Kashani1, Ali A Mearza.   

Abstract

Ciclosporin is a calcineurin inhibitor that acts by primarily inhibiting the action of T cells. Clinical trials in the early 1980s demonstrated that systemic ciclosporin was a promising steroid-sparing agent and was also effective in patients who are refractory to treatment with corticosteroids. However, recent years have witnessed the emergence of safer immunosuppressive agents due to the poor side-effect profile of systemic ciclosporin. Topical ciclosporin, however, has a much improved safety profile and is still used to treat a variety of ocular surface disorders including dry eye syndrome, vernal and atopic keratoconjunctivitis, severe blepharitis and high-risk corneal graft patients. This article reviews the uses and safety profile of systemic and topical ciclosporin in ophthalmology, as well as discussing alternative therapeutic agents available.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18171316     DOI: 10.1517/14740338.7.1.79

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  5 in total

1.  Update on the Management of High-Risk Penetrating Keratoplasty.

Authors:  Sayena Jabbehdari; Alireza Baradaran Rafii; Ghasem Yazdanpanah; Pedram Hamrah; Edward J Holland; Ali R Djalilian
Journal:  Curr Ophthalmol Rep       Date:  2017-02-02

Review 2.  Systemic cyclosporine and corneal transplantation.

Authors:  Mohammed Ziaei; Fatemeh Ziaei; Bita Manzouri
Journal:  Int Ophthalmol       Date:  2016-02       Impact factor: 2.031

3.  Cyclosporine for ocular inflammatory diseases.

Authors:  R Oktay Kaçmaz; John H Kempen; Craig Newcomb; Ebenezer Daniel; Sapna Gangaputra; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; Douglas A Jabs; Grace A Levy-Clarke; C Stephen Foster
Journal:  Ophthalmology       Date:  2010-01-19       Impact factor: 12.079

4.  Cyclosporine Amicellar delivery system for dry eyes.

Authors:  Han Kang; Kwang-Ho Cha; Wonkyung Cho; Junsung Park; Hee Jun Park; Bo Kyung Sun; Sang-Min Hyun; Sung-Joo Hwang
Journal:  Int J Nanomedicine       Date:  2016-06-21

5.  Recurrent contracted sockets treated with personalized, three-dimensionally printed conformers and buccal grafts.

Authors:  Alw Groot; Jelmer S Remmers; Roel Jhm Kloos; Peerooz Saeed; Dyonne T Hartong
Journal:  Eur J Ophthalmol       Date:  2021-03-11       Impact factor: 2.597

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.